About: Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database
Creator	Mano, Nariyasu Miyazaki, Makoto Murai, Yuriko Noda, Aoi Obara, Taku Oyanagi, Gen Sakai, Takamasa Tsuchiya, Masami
Source	PMC
abstract	BACKGROUND: There are no reports on investigations of the characteristics of adverse drug reaction (ADR) reports for pediatric patients in the Japanese Adverse Drug Event Report database (JADER) and the utility of database for drug safety surveillance in these patients. METHOD: We aimed to evaluate ADR reports for pediatric patients in the JADER. We used spontaneous ADR reports included in the JADER since April 1, 2004, to December 31, 2017, which was downloaded in April 2018. In a total of 504,407 ADR reports, the number of spontaneous reports was 386,400 (76.6%), in which 37,534 (7.4%) were unknown age reports. After extraction of 27,800 ADR reports for children aged < 10 and 10–19 years, we excepted for ADR reports associated with a vaccine (n = 6355) and no-suspected drug reports (n = 86). A total of 21,359 (4.2%) reports were finally included in this analysis. RESULTS: More than half of the ADR reports were for children aged < 10 years. Approximately 30% of ADR reports had multiple suspected drugs, which did not differ by age. The percentages of fatal outcomes of ADRs among patients aged < 10 and 10–19 years were 4.7 and 3.9%, respectively. The most frequently reported drug, reaction, and drug-reaction pair were oseltamivir, abnormal behavior, and oseltamivir and abnormal behavior, respectively. CONCLUSION: We clarified the characteristics of ADR reports for Japanese children by using the JADER. ADR report databases, especially those for pediatric patients, are valuable pharmacovigilance tools in Japan and other countries. Therefore, a proper understanding of the characteristics of the ADR reports in the JADER is important. Additionally, potential signals for ADRs in pediatric patients should be monitored continuously and carefully.
has issue date	2020-05-24(xsd:dateTime)
bibo:doi	10.1186/s40360-020-00412-7
has license	cc-by
sha1sum (hex)	4d93741620a6fd886b52de52716ba14c1370236e
schema:url	https://doi.org/10.1186/s40360-020-00412-7
resource representing a document's title	Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database
has PubMed Central identifier	PMC7245855
schema:publication	BMC Pharmacol Toxicol
resource representing a document's body	covid:4d93741620a6fd886b52de52716ba14c1370236e#body_text
is schema:about of	named entity 'Zanamivir' named entity 'After' named entity 'patients' named entity 'ADRs' named entity 'ADRs' named entity 'drugs' named entity 'adverse drug reaction' named entity 'frequently' named entity 'Sodium valproate' named entity 'clarified' named entity '2018' named entity 'ADR' named entity 'aged' named entity 'Acetaminophen' named entity 'vaccine' named entity 'spontaneous' named entity 'ADR' named entity 'Carbamazepine' named entity 'signals' named entity 'Prednisolone' named entity 'Event' named entity 'age' named entity 'tools' named entity 'BMC Pharmacology' named entity 'Drug' named entity 'Adverse' named entity 'Cyclosporine' named entity 'pediatric patients' named entity 'Toxicology' named entity 'Methotrexate' named entity 'ADR' named entity 'Acetaminophen' named entity 'Oseltamivir' named entity 'ADR' named entity 'ADR' named entity 'ADRs' named entity 'ADRs' named entity 'Prednisolone' named entity 'ADR' named entity 'Carbamazepine' named entity '1.6' named entity 'Adverse Drug Event' named entity 'Prednisolone' named entity 'ADR' named entity 'adverse drug reaction' named entity 'Polypharmacy' named entity 'Pediatric' named entity 'adverse reaction' named entity 'categorical variable' named entity 'anti-influenza' named entity 'demographic information' named entity 'data analyses' named entity 'ADRs' named entity 'Gene Therapy' named entity 'birth defects' named entity 'ADRs' named entity 'adverse events' named entity 'cerebrovascular disorders' named entity 'vaccine' named entity 'medical institutions' named entity 'database' named entity 'France' named entity 'Pharmaceutical' named entity 'attention deficit disorder' named entity 'adverse events' named entity 'clinical trials' named entity 'ADRs' named entity 'drug safety' named entity 'causality' named entity 'Japan' named entity 'disability' named entity 'Spain' named entity 'drug safety' named entity 'ADRs' named entity 'healthcare professional' named entity 'pharmacist'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software